SEC31 homolog B, COPII componentGenealiases: SEC31B-1 · SEC31L2
Q-omics provides the consensus-scored SEC31B profile across patient tissues and cancer cell-line models. SEC31B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SEC31B is differentially expressed in 9, with the highest sampling consensus in BRCA. Additionally, SEC31B protein abundance shows 23,003 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, BRCA, and LSCC as cancer lineages where SEC31B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SEC31B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SEC31B survival associations across molecular data types. SEC31B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SEC31B RNA expression–survival associations across cancer types. High SEC31B expression shows unfavorable associations in KIRC and KICH, but favorable associations in HNSC, BLCA, SKCM and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SEC31B RNA expression.
This table summarizes SEC31B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in BRCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SEC31B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SEC31B shows lower tumor expression in BRCA, LUSC and HNSC and higher tumor expression in COAD, KIRC and LIHC. The BRCA box plot shows higher SEC31B RNA expression in normal versus tumor tissue (log2 FC = −0.943, t-test p < 0.001).
This table shows molecular features associated with SEC31B in patient tissues and cancer cell lines. In patient samples, SEC31B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SEC31B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
